EAEhed Muhammed Aymaz

Ehed Muhammed Aymaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ehed Muhammed Aymaz has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Computational Analysis of Nucleotide Substitutions in a CD47 Aptamer: Structural and Energetic Insights

    by Sümeyye Altunok, Emre Can Buluz, Ehed Muhammed Aymaz

    The Cluster of Differentiation 47 (CD47)–signal regulatory protein alpha (SIRPα) immune checkpoint is a key regulator of tumor immune evasion and a promising target in cancer immunotherapy. To overcome the limitations of monoclonal antibodies, this study aimed to identify high-affinity nucleic acid aptamers targeting CD47. A systematic single-nucleotide mutagenesis workflow was performed on a known CD47-binding DNA aptamer to generate 270 single-point variants, enabling unbiased evaluation of each nucleotide position. The variants were first screened for structural stability, yielding 81 structurally stable candidates. These candidates were then subjected to molecular docking against CD47, and 45 variants showed improved docking scores compared with the native aptamer. The docking score improved from −226.07 for the native aptamer to −301.94 for the best-performing variant. Based on structural stability and docking performance, the ten top-ranked candidates were selected for molecular dynamics simulations. These variants exhibited improved conformational stability, as reflected by lower root-mean-square deviation (RMSD) and root-mean-square fluctuation (RMSF) values and increased hydrogen bonding, with Seq198 and Seq262 showing the most stable profiles. Binding free energy calculations confirmed improved affinity. The native aptamer exhibited a ΔTOTAL of −97.16 kcal/mol, whereas Seq198 (−173.13 kcal/mol), Seq244 (−152.35 kcal/mol), and Seq112 (−147.19 kcal/mol) showed markedly stronger binding. Seq198 emerged as the most promising candidate. These findings demonstrate that systematic computational mutagenesis is an effective strategy for optimizing aptamer performance and identifying high-affinity CD47-targeting candidates.

  • Open Access

    Integrative genomic and functional characterization of ADAMTS3 reveals its inflammatory regulation via NF‐κB and STAT3 pathways in osteosarcoma

    by Ehed Muhammed Aymaz, Meltem Alper, Feyza Nur Sav, Tuğşen Aydemir, Feray Köçkar

    Osteosarcoma (OS) is an aggressive bone malignancy characterized by genomic instability and extensive extracellular matrix (ECM) remodeling. Members of the ADAMTS family are matrix‐associated proteases implicated in tumorigenesis; however, their roles in OS remain poorly defined. This study provides a comprehensive genomic, transcriptomic, and functional analysis of the ADAMTSs in OS, with particular focus on ADAMTS‐3. Copy number alterations and mRNA expressions of ADAMTS genes were analyzed using the TCGA datasets. Gene set enrichment analysis and co‐expression analyses identified biological processes associated with ADAMTS‐3. Mechanistic studies investigated tumor necrosis factor‐alpha (TNF‐α) regulation of ADAMTS‐3 in OS cells. Genomic profiling revealed frequent amplification and high mRNA expression of ADAMTS4, ADAMTS12, ADAMTS16, and ADAMTS17, indicating potential oncogenic activity. ADAMTS‐3 was markedly overexpressed in OS tissues and cell lines, showing strong positive correlations with inflammatory (IL6, STAT3, NF‐κB) and matrix‐remodeling (MMP2, MMP9) genes. Functional enrichment indicated that ADAMTS‐3 is associated with ECM organization, immune response regulation, and epithelial‐mesenchymal transition. Mechanistically, TNF‐α induced ADAMTS‐3 transcription via activation of MEK, PI3K, JNK, and NF‐κB pathways, with STAT3 and NF‐κB by enhancing promoter activity. These findings identify ADAMTS‐3 as an inflammation‐responsive gene that links inflammatory signaling to ECM remodeling and tumor invasiveness in OS, representing a potential molecular bridge.